The risk here actually is not super “high” as such (as in here) as it’s running at half the value without any of the phase 2 trial data etc
My take on it is Only when it is running at proper value for everything that is going on with it doesn’t it go into a more risky (price)category when the bigger more meaty phase trial data comes or is due to come out
Ann: Imugene Advances to Phase 2 in Gastric Cancer Trial, page-73
-
- There are more pages in this discussion • 136 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.9¢ | 3.9¢ | 3.7¢ | $388.1K | 10.11M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 146314 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 2536521 | 6 |
View Market Depth
| Last trade - 16.10pm 02/12/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
